The abstract is read at the publisher; the summary is JClub's.
Natalizumab cessation in adults with relapsing-remitting multiple sclerosis (RRMS) is linked to a 41.7% pooled relapse risk within 12 months, with sensitivity showing 36.8%.
- Why it matters: Stopping natalizumab can lead to substantial disease reactivation, and clinicians need evidence to plan discontinuation and compare dosing strategies for efficacy and safety.
- What they did: A PRISMA-guided systematic review and meta-analysis (PROSPERO: CRD420251103014) searched 2015–2025 studies and pooled 12-month post-cessation relapse from 4 studies (n=861), with ARR and PML assessed separately.
- The result: There was no consistent ARR difference between standard interval dosing (SID) and extended interval dosing (EID), and PML risk showed no significant difference (RR 0.70, 95% CI 0.20–2.54), while disability progression was too heterogeneous to pool.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.